Numerate entered into an agreement with Takeda to use its artificial intelligence engines to develop clinical candidates in multiple specialties.
Here's what you should know:
1. Numerate will identify clinical candidates aimed at Takeda's oncology, gastroenterology and central nervous system disorders sectors.
2. Numerate's artificial intelligence platforms will completely drive the drugs' development.
3. Numerate CEO and President Guido Lanza said in a release, "We expect to produce multiple clinical candidates, while also continuing to refine, validate and expand our proprietary AI-driven platform as we work across a broad range of target types and drug design challenges."
4. The companies didn't reveal specific financial terms, but indicated the deals have a combination of milestone payments and royalties based on drug performance.